ICHOR reperfusion system receives FDA clearance


Euphrates Vascular, a company focused on the treatment of vascular occlusions, recently received 510(k) clearance for sale of its ICHOR Percutaneous Reperfusion System.

ICHOR is a Percutaneous Reperfusion System designed to treat organised thrombus and embolic events in the peripheral vasculature. ICHOR is a “one size fits all” system that replicates the standard of care of surgical embolectomy or thrombectomy in a minimally invasive manner:

  • percutaneous approach reduces surgical complications
  • mechanism of action minimises blood loss associated with aspiration
  • mechanism of action does not require drug therapy which potentiates a reduction of common bleeding complications associated with lytics
  • does not require general anaesthesia
  • does not require the need for capital equipment (disposable only)
  • easily adoptable by interventionalists
  • incorporates a health economic element intended to make ICHOR a first line therapy for physicians, hospitals and office-based labs.

    ICHOR will be the first marketable product for Euphrates Vascular with the Pulse NanoMED technology in the pipeline. The ICHOR and Pulse NanoMED systems were both designed to target vascular occlusions by eliminating the need for surgery or drug therapies and both attempt to treat further and deeper by overcoming today’s size limitations in material science.

    “ICHOR will be an extraordinary tool in the clot management toolbox due to its ability to handle the organised clot many physicians struggle to treat. The Pulse NanoMED system may allow for us to change our approach in treating occlusions in areas such as the lower limb, the diabetic foot and perhaps in the neurovasculature, by simply being able to access the most tortuous anatomy and the smallest vasculature. The Pulse NanoMED system can enable us to go where no other devices have gone before,” said Troy Long, vascular interventional radiologist.


Please enter your comment!
Please enter your name here